Pharvaris (NASDAQ:PHVS) Reaches New 52-Week High – Here’s What Happened

Pharvaris N.V. (NASDAQ:PHVS) hit a new 52-week high during trading on Thursday . The company traded as high as $34.43 and last traded at $34.0050, with a volume of 7619 shares changing hands. The stock had previously closed at $33.29.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating on shares of Pharvaris in a report on Tuesday, June 16th. Royal Bank Of Canada decreased their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. UBS Group set a $74.00 price target on shares of Pharvaris in a research report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Finally, Wall Street Zen upgraded shares of Pharvaris from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $49.64.

Pharvaris Stock Up 3.5%

The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of -10.85 and a beta of -2.35. The business’s 50 day simple moving average is $30.37 and its 200-day simple moving average is $27.88.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, analysts expect that Pharvaris N.V. will post -3.22 earnings per share for the current year.

Insiders Place Their Bets

In other Pharvaris news, Director Robert Glassman sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $29.82, for a total transaction of $298,200.00. Following the completion of the transaction, the director directly owned 10,500 shares in the company, valued at $313,110. The trade was a 48.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Peng Lu sold 15,000 shares of the company’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.24, for a total value of $453,600.00. Following the sale, the insider owned 66,083 shares of the company’s stock, valued at $1,998,349.92. The trade was a 18.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 215,209 shares of company stock valued at $6,431,945 over the last three months. 11.84% of the stock is owned by corporate insiders.

Institutional Trading of Pharvaris

Institutional investors and hedge funds have recently modified their holdings of the business. Seven Fleet Capital Management LP boosted its stake in Pharvaris by 472.3% in the first quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock valued at $8,947,000 after buying an additional 261,355 shares in the last quarter. DV Trading LLC bought a new position in shares of Pharvaris in the first quarter worth about $4,067,000. Stempoint Capital LP lifted its holdings in shares of Pharvaris by 48.4% in the first quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock worth $2,447,000 after acquiring an additional 28,248 shares during the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Pharvaris by 23.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock valued at $2,981,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Amundi grew its holdings in shares of Pharvaris by 12.0% during the 1st quarter. Amundi now owns 30,952 shares of the company’s stock valued at $874,000 after purchasing an additional 3,312 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.